New colleague at senzaGen

Welcome Andy Forreryd

Andy has started his position as Scientist with us here at SenzaGen after defending his doctoral thesis GARD – Genomic Allergen Rapid Detection, From Biomarker Discovery towards a State-of-the-art Testing Platform for Chemical Sensitizers at the Department of Immunotechnology, Lund University.

Andy strengthens SenzaGen’s scientific team with his genuine expertise on the GARD platform, which formed the basis for his thesis. Andy is a specialist in biomarker discovery and statistical analysis of multivariate genomic data and has long experience in both cell culturing and in various technologies for gene expression measurements. He also has great experience in communicating research to both a scientific and public audience.

As The faculty opponent of the doctoral thesis, Dr Gavin Maxwell, stated when starting his opposition: “The thesis in one of the most complete analyses in the field”. We can only agree.

We are very happy to have you in our team, Andy!

 

Link to thesis

GARD – Genomic Allergen Rapid Detection, From Biomarker Discovery towards a State-of-the-art Testing Platform for Chemical Sensitizers at the Department of Immunotechnology, Lund University.

 

The Immunotoxicity testing in the 21th century seminar

Welcome to the seminar

Immunotoxicity testing in the 21th century – recent developments within prediction of immunotoxicity using alternative methods.

The seminar will take place at the Medicon Village Aula (Hörsalen) on November 23, 2017 with the support from SenzaGen and Medicon village

Program:

13.15-13.30     Welcome
Prof. Malin Lindstedt, Dept. of Immunotechnology
Kerstin Jakobsson, Vice President, Medicon Village

13.30-14.00     From pathways to people: applying the skin sensitization adverse outcome pathway (AOP) 
Dr. Gavin Maxwell, Unilever’s Safety & Environmental Assurance centre, UK

14.00-14.30     Towards an AOP for chemical respiratory allergy
Prof. Ian Kimber, University of Manchester, UK

14.30-15.00     Coffee

15.00-15.30     Application of novel in vitro methods for the discovery of safe innovative medicines
Dr Jorrit Hornberg, Discovery Safety at AstraZeneca

15.30-16.00     Application of the AOP concept to structure the available in vivo and in vitro mechanistic data for allergic sensitization to food protein
Dr Erwin Roggen, 3Rs Management and Consulting ApS

16.00-16.30     Progress towards GARDskin validation and GARDair implementation
Dr Henrik Johansson, SenzaGen AB

Please register before Nov 15 to maria.klement@immun.lth.se

Link to program

Research on GARDprotein published in highly reputed scientific journal

SenzaGen announces that research findings that support the development of a new application area for the company’s test platform GARDTM have been published in the highly reputed journal Toxicology in Vitro. The research described in the publication constitutes the basis of GARDprotein – a test method currently being developed to be able to eliminate allergy-inducing proteins from today’s and tomorrow’s foodstuffs.

In the publication, An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract, a research group from Lund University describes its successful work on the identification of a unique set of genes, gene signature, that makes it possible to evaluate the allergenic characteristics of proteins. This gene signature constitutes the basis of the development of GARDprotein, a test that has the potential to meet the growing needs of the food industry to avoid allergy-inducing substances in their products.

As previously announced, a scientific evaluation of GARDprotein has already been carried out. The positive results of this evaluation were recently announced at The 3rd ImpARAS Conference in Helsingør, Denmark. The results show that with a high degree of accuracy and reliability the test method can reduce the risk that proteins in food are incorrectly categorized as allergenic or that their allergenic properties are not detected in time.

The article :
An alternative biomarker-based approach for the prediction of proteins known to sensitize the respiratory tract. Zeller KS, Johansson H, Lund TØ, Kristensen NN, Roggen EL, Lindstedt M.

Published in Toxicology In Vitroonline available via this link:
https://www.ncbi.nlm.nih.gov/pubmed/29017774

For more information, please contact
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

SenzaGen CEO Anki Malmborg Hager presents at Swetox conference on future research without animal testing

SenzaGen’s CEO, Anki Malmborg Hager, gives a presentation today on October 17, entitled: A new, animal-free allergy test with the goal of becoming a “golden standard” for risk assessment in the cosmetics and chemical industry. An innovation company with the next generation tests tells their story. The presentation will take place during the SWETOX conference at Hasselbacken in Stockholm

The conference, The Future on Research on Animal-Free Methods, is organized by SWETOX and is part of the communication “New Animal-Free Methods to Meet the Need for Safe Chemicals” funded by the Research Council FORMAS. SWETOX visions on reaching A Safe Chemical World and Toxicological Risk Assessment Without Animal Experiments, will be the starting point of the day.

The conference aim is to bring innovative people together and it is led by speakers from several pioneering research areas in animal-free research. The conference also addresses the political arena with closing discussions with Swedish politicians on site.

SWETOX is a national research centre for toxicology, a collaboration between eleven Swedish universities. The hub of the cooperation is a state-of-the-art and well-equipped facility in Gärtuna, outside Södertälje.

For more information about the conference (Swedish)
http://swetox.se/event/swetox-replacement-workshop/

For more information
Anki Malmborg Hager, vd, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

Malin Lindstedt, founder of SenzaGen and GARD, is awarded the NYTÄNKAREN 2017 (INNOVATIVE THINKER 2017) prize by the Swedish foundation Research Without Animal Experiments

SenzaGen’s co-founder, Professor Malin Lindstedt, has been awarded the Nytänkaren 2017 (Innovative Thinker 2017) Prize and SEK 400,000 by the Swedish fundation for Research Without Animal Experiments for her work on the development of animal-free testing methods. The prize was awarded today, 16 October at a ceremony at Research Without Animal Experiments offices in Stockholm.

Professor Malin Lindstedt receives the prize for her successful development of advanced testing methods that can reduce and replace the use of animals in the risk assessment of chemicals and consumer products. Malin Lindstedt works at Lund University’s Department of Immunotechnology, where she has directed the research that lies behind the series of allergy tests based on cell-based gene analysis that are now marketed under the name GARD. Under her direction, a research team started by developing a test for skin allergies. They then went on to develop a test to determine which substances can cause respiratory allergies, and most recently a test that can analyze proteins associated with food allergies.

While working on the development of the technology behind GARD, Malin Lindstedt founded SenzaGen, the company which is now responsible for making this technology available on the global market. The first test to be developed, GARDskin, is already seeing limited use. GARDskin is at the present time undergoing a validation process for inclusion in the OECD Chemical Test Guidelines, which would result in the method achieving its international breakthrough as an eligible method that meets regulatory requirements for the risk assessment of chemicals.

The prize from Research Without Animal Experiments highlights the practicability of using advanced methods to continue to reduce and replace the use of animals in the risk assessment of chemicals and consumer products both inside and outside Sweden. With the NYTÄNKAREN prize and its associated funding, Research Without Animal Experiments wishes particularly to support the research team’s ambitions to continue their development of allergy tests.

 

News about the prize can be viewed on the Research Without Animal  Experiments website:

http://forskautandjurforsok.se/knappar-pa-startsidan/nytankaren-2017/

 

For more information

Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

Grundaren av SenzaGen och GARD, Malin Lindstedt, tilldelas priset som NYTÄNKAREN 2017 av stiftelsen Forska Utan Djurförsök

SenzaGens medgrundare, Professor Malin Lindstedt har tilldelats utmärkelsen Nytänkaren 2017 och 400 000 kronor av stiftelsen Forska Utan Djurförsök för sitt arbete med utveckling av djurfria testmetoder. Idag delades priset ut vid en sammankomst hos stiftelsen Forska Utan Djurförsök Stockholm

Professor Malin Lindstedt får priset för sin framgångsrika utveckling av avancerade testmetoder som kan minska och ersätta användningen av djur vid riskbedömning av kemikalier och konsumentprodukter.  Malin Lindstedt arbetar på Institutionen för Immunteknologi, Lunds universitet, där hon lett forskningen som ligger bakom den serie allergitester som nu marknadsförs under namnet GARD och som utgår från cellbaserade genanalyser. Under hennes ledning började en forskargrupp med att utveckla ett test för hudallergier. De har sedan fortsatt utvecklingen med ett test för att avgöra vilka ämnen som kan orsaka luftvägsallergier, och nu senast ett test som kan analysera proteiner som är förknippade med matallergier.

Under sitt arbete med att utveckla teknologin bakom GARD grundade Malin Lindstedt företaget SenzaGen, som nu ansvarar för att göra teknologin tillgänglig på den globala marknaden. Det först utvecklade testet, GARDskin, har redan börjat användas i begränsad omfattning. GARDskin ingår i en valideringsprocess för att upptas i OECD:s testriktlinjer för kemikalier, vilket skulle leda till att metoden får internationellt genomslag som valbar metod för att uppfylla regulatoriska krav för riskbedömning av kemikalier.

Priset från Forska utan Djurförsök belyser möjligheten att med avancerade metoder fortsätta att minska och ersätta användning av djur vid riskbedömning av kemikalier och konsumentprodukter i och utanför Sverige. Forska Utan Djurförsök vill med NYTÄNKAREN och tillhörande anslag särskilt stödja forskargruppens ambitioner att fortsätta utvecklingen av allergitester.

Nyheten om priset hos Stiftelsen Forska Utand Djurförsök
http://forskautandjurforsok.se/knappar-pa-startsidan/nytankaren-2017/

 

För mer information:
Anki Malmborg Hager, vd, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telefon: 0768 284822

 

 

New colleague at SenzaGen

Welcome to SenzaGen Henrik Appelgren!

Henrik has started his position as Chief Scientific Officer with us here at SenzaGen this week. Henrik is a biologist with a PhD in genetic toxicology. He has been working at the Swedish Chemicals Agency for 15 years, where he worked as Sweden’s national coordinator in the OECD Test Guideline Programme. Henrik has a deep knowledge in alternative test methods and of regulatory work in the chemical industry – both nationally and internationally. He also has long experience of health risk assessments of chemicals in all European legislation. He is, and has been, a member of several scientific expert councils including FORMAS, the Swedish Research Council, the Swedish Fund for Research Without Animal Experiments, the Scandinavian Society for Cell Toxicology and EUToxRisk.

Henrik strengthens SenzaGen’s management for the commercialization of the GARD tests and prior to the company’s planned listing on Nasdaq First North.

We are very happy to have you in our team, Henrik!

SenzaGen is presenting at hosted session at the EUROTOX Congress in Bratislava

SenzaGen new Chief Scientific officer Hernik Appelgren will give a presentation on 21st century testing for skin sensitisation and updates on application of the GARD platform at The 53rd  European Congress of the European Societies of Toxicology, EUROTOX, on the 12th of Sept. SenzaGen is also Exhibiting at the congress and presenting two posters

The meeting promises scientific sessions houndreds of abstract presentations, exhibitors meetings, continuing education courses, awards presentations, receptions,  and  an exhibition area for exhibitors offering you the latest information on services and technology
Presentation details
Tuesday 12 Sep 10-11 AM | 
Memories, Hotel Sheraton
21st Century Sensitisation testing: Can one test be stand alone? Regulatory challenges and GARD applications update
.

Presented by: Henrik Appelgren, Chief Scientific Officer and regulatory expert at SenzaGen

Allergy is a growing health problem in humans. The data requirements for the assessment of sensitisation in chemical legislations have been based on animal assays, which until now have served as the golden standard. However, in vitro assays have been developed which need to be combined in order to address all key events for sensitisation to fulfil the demands in e. g., Reach. However, The Genomic Allergen Rapid Detection Skin (GARDskin) assay addresses all the key regulatory questions regarding sensitisation, including potency – How? This session we will give an update on the validation status and the different applications of GARD.

Posters
ID 668 | Session 2 | Board no P-04-02-07 | Monday, Sept 11 from 15:00
Transferability of the GARDskin assay to two independent laboratories.

ID 438 | Session 4 | Board number P-09-02-31 | Tuesday, Sept 12 from 15:00
The GARD platform for potency assessment of skin sensitizing chemicals

New colleague at SenzaGen

Welcome to SenzaGen Anna Chérouvrier Hansson!

Anna has started her position as Chief Commercial Officer with us here at SenzaGen this week. Anna comes from Camurus, a pharmaceutical company developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions. At Camurus, Anna was Director of Marketing and responsible for the Medical Device Business Unit. She has previously worked as Head of Business Development Life Science at Invest in Skåne, Partner at Zitha Consulting and in a number of senior positions in European pharmaceutical and chemical companies. Anna was born in France, studied and worked in Germany and Luxembourg before moving to Sweden in 2000 to study a Master in Business Administration and Business Law and decided to stay. Anna strengthens SenzaGen’s management for the commercialization of the GARD tests and prior to the company’s planned listing on Nasdaq First North.

We are very happy to have you in our team, Anna!

senzagen skin derma

Meet us in Almedalen – The researchers behind the GARDtest and SenzaGen’s lab technicians on site.

Meet Andy Forreryd from Lund University and Angelica Johansson from SenzaGen in the organisation of Research Without Animal Experiments, 6th and 7th of July. During two seminars, Andy will tell us about the research behind GARD. There will be opportunities for questions and hands on practical lab work so that you can experience and see how the test works.

With research money from different organisations, including Research Without Animal Experiments, the university has developed a unique allergy test that with higher precision than existing tests can determine if a chemical can induce skin allergy. The test is carried out in test tubes and replaces the need for animal testing when safety testing chemicals.

The GARDtestet is now owned, sold and marketed by SenzaGen AB for global commercialization with the aim of becoming a new industry standard on the international chemical safety testing market. Angelica Johansson is on site to talk about GARD’s journey from laboratory to global market. Link in Swedish.